Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-04-14
Tempus AI, Inc.
Tempus sells genomic diagnostics, AI-enabled clinical workflow tools, and de-identified data analytics to physicians, health systems, and life sciences companies.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Data Rights and Workflow Create a Gated Compounding Story
A rare mix of diagnostics, clinical workflow, and regulated data rights gives this business a credible path to outgrow healthcare peers through 2031. The debate is whether scientific proof and cash discipline arrive quickly enough for the market to keep valuing it as a platform rather than a lab.

Analysis

Thesis
Tempus can compound into a meaningfully larger healthcare AI platform if it turns its diagnostics-fed data rights and physician workflow footprint into recurring evidence, software, and operating-layer revenue while proving that growth no longer depends on external capital.
Last Economy Alignment
Cheaper cognition helps Tempus because it owns scarce clinical/genomic data rights and embedded workflow, so value should shift toward its trusted data and action layer rather than generic AI interfaces.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.6x (from 5 most recent analyses)
Reasoning
The upside case is not frontier-model dominance. It is sustained diagnostics share gains, repeatable Lens-style enterprise demand, and deeper workflow embed through Hub, Tempus One, and follow-up services. If that mix shifts revenue toward stickier, higher-value data and software while burn improves, investors can keep valuing the business above pure diagnostics peers even with some multiple discipline.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The key risks are not whether Tempus can ship AI features, but whether it can prove repeatable clinical and pharma value fast enough to deepen workflow control, convert backlog into durable revenue, and self-fund growth. If those gates slip, the business can still grow while the market values it more like a diagnostics company than a healthcare data platform.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.68
They control hard-to-recreate clinical and genomic data plus the workflow where doctors order and review tests, so cheaper AI makes their data more valuable rather than replacing them. The risk is that regulators, buyers, or financing markets slow the move from smart testing company to trusted operating layer.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$80.14
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case